Alpha Cognition Inc. has outlined its strategic priorities for 2026, focusing on the commercial expansion of ZUNVEYL, a patented acetylcholinesterase inhibitor for Alzheimer's disease. The company aims to grow ZUNVEYL’s prescriber base to approximately 2,000 healthcare providers and increase penetration in nursing homes. Alpha Cognition plans to complete or initiate three studies in 2026 supporting ZUNVEYL's impact in Alzheimer's patients in long-term care settings. The company also intends to expand payor coverage through additional pharmacy benefit manager contracts and explore royalty monetization opportunities from licensing outside the US, particularly in Asia. Commercialization efforts are expected to support operating profitability in 2027. The company will continue to explore real-world evidence-based studies for ZUNVEYL and assess its use in cognitive impairment associated with mild traumatic brain injury.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Cognition Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260107765998) on January 07, 2026, and is solely responsible for the information contained therein.